Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumLoretta J. Nastoupil, Frederick L. Locke, Matthew A. Lunning et al.|Journal of Clinical Oncology|2020Cited by 782
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic LeukemiaTait D. Shanafelt, Martin S. Tallman, Xin V. Wang et al.|New England Journal of Medicine|2019Cited by 735
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantationRizwan Romee, Jeffrey S. Miller, Sarah Cooley et al.|Blood|2018Cited by 406
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLLIan W. Flinn, Stephan Stilgenbauer, Peter Hillmen et al.|Blood|2018Cited by 341
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and <i>In Vivo</i> Clearance of B Cell LymphomasMaximillian Rosario, Todd A. Fehniger, Bai Liu et al.|Clinical Cancer Research|2015Cited by 147